BRIC Nations to Outgrow Traditional Markets in Biologics

Monday 2 July 2012, Amsterdam

Biologics industry growth in the BRIC countries (Brazil, Russia, India and China) is expected to outpace traditional markets, according to the new Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth report.

The report states that, until recently, these emerging markets did not figure in the plans of the major pharmaceutical companies, but due to financial and political developments they are now seen as important countries in the pharmaceutical industry.

In terms of growth, it is anticipated that the BRIC countries will outstrip traditional markets like Europe and the US, albeit from a lower revenue base, in the years to come.

This report states these burgeoning economies are projected to account for over a quarter of the global biological market revenues by 2015.

The biologic sector is increasingly important to the pharma industry due to stagnation in R&D productivity and concerns over the so-called “patent cliff”, with an established first generation of biologic therapies representing 24 of the top selling pharmaceutical products worldwide.

While the patent cliff has largely affected small-molecule synthetic drugs which have been the staple of pharmaceutical prosperity for decades, biologic treatments are emerging as a greater standard of care and are more difficult to replicate and manufacture.

These therapies are biological rather than chemical developments that promise greater effectiveness due to their capacity to target the underlying cause of disease and form personalized medicines.

This report discusses the growing importance of biologics and emerging markets. The key classes of biologic medicines are described, along with their therapeutic applications and importance.

In addition, significant pipeline developments in advanced clinical trials are identified. Selected companies that are already present in the biologic field are also profiled in this report.

Furthermore, the BRIC markets are described in detail. This covers their importance as pharmaceutical markets, including relevant background information such as pricing and government policies towards foreign companies, and provides a general country analysis for each.

Trends of importance to pharmaceutical market planners are also discussed, as well as strategies that are relevant for foreign companies seeking to gain a foothold in these markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.